Work

Comprehensive Whole‐Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review

Year: 2025

Type: article

Abstract: Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade-long expertise in managing recurrent cases, we advocate the adoption of Programmed Death-1 (PD-1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.70418

Authors: PengNan Hu, Di Chen, Jun Yu, Hua Mi

Institutions: Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820